Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2033³â)
Hemoglobinopathy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
Persistence Market Research´Â À̹ø¿¡ ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀå¿¡ °üÇÑ ±¤¹üÀ§ÇÑ ¸®Æ÷Æ®¸¦ ¹ßÇàÇß½À´Ï´Ù. ÃËÁø¿äÀΡ¤µ¿Ç⡤±âȸ¡¤°úÁ¦ µîÀÇ ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» »ó¼¼ÇÏ°Ô Æò°¡Çϰí, ½ÃÀå ±¸Á¶¿¡ °üÇÑ »ó¼¼ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
- Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀå ±Ô¸ð(2024³â) : 7,882¾ï ´Þ·¯
- ¿¹Ãø ½ÃÀå ±Ý¾×(2033³â) : 1Á¶ 4,723¾ï ´Þ·¯
- ¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2024-2033³â) : 7.2%
Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀå - Á¶»ç ¹üÀ§
Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀº ÀûÇ÷±¸³» Çì¸ð±Û·ÎºóÀÇ ±¸Á¶¿Í ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À¯Àü¼º ÁúȯÀÇ Áø´Ü, Ä¡·á ¹× °ü¸®¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ÁÖ·Î °â»ó ÀûÇ÷±¸ ºóÇ÷, ÁöÁßÇØºóÇ÷ ¹× ±âŸ ´ú ÈçÇÑ Çì¸ð±Û·Îºó ÀÌ»ó°ú °°Àº Áúº´¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â Áø´Ü °Ë»ç, Ä¡·áÁ¦, À¯ÀüÀÚ Ä¡·á µî ´Ù¾çÇÑ Á¦Ç°°ú ¼ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. Ä¡·áÀÇ ¿øµ¿·ÂÀº ÀÎ½Ä Áõ°¡, Ä¡·á¹ýÀÇ ¹ßÀü, Àü ¼¼°è¿¡¼ À¯Àü¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ ½ÃÀåÀº ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ, º´¿ø, Ŭ¸®´Ð ¹× ¿¬±¸ ±â°ü¿¡ ¼ºñ½º¸¦ Á¦°øÇÏ¿© Á¶±â Áø´Ü ¹× Ä¡·á °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ÃËÁø¿äÀÎ:
Çì¸ð±Û·Îºó ÀÌ»ó Áúȯ ¼¼°è ½ÃÀåÀ» ÁÖµµÇÏ´Â ¸î °¡Áö ÁÖ¿ä ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ¿ì¼±, »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä«, ³²¾Æ½Ã¾Æ, ÁöÁßÇØ ¿¬¾È Áö¿ª µîÁö¿¡¼ ÀÌ»ó Ç÷»ö¼Ò ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ³ªÀº Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¶±â °ËÁø ÇÁ·Î±×·¥À» Á¦°øÇÏ´Â Á¤ºÎÀÇ ±¸»ó°ú ÇÔ²² ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·áÀÇ ¹ßÀü°ú À¯ÀüÀÚ ±³Á¤À» À§ÇÑ CRISPR ±â¼ú°ú °°Àº »õ·Î¿î Ä¡·á ¿É¼ÇÀº ÀÌ·¯ÇÑ Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ »êÀü Áø´Ü°ú º¸±ÕÀÚ ¼±º°¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Çì¸ð±Û·Îºó ÀÌ»ó ÁúȯÀÇ ÀüÆÄ¸¦ ¿¹¹æÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖÀ¸¸ç, ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀº À¯¸ÁÇÑ Àü¸Á¿¡µµ ºÒ±¸ÇÏ°í Æ¯Á¤ °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ƯÈ÷ Çì¸ð±Û·Îºó ÀÌ»ó ÁúȯÀÇ À¯º´·üÀÌ °¡Àå ³ôÀº ¸¹Àº Àú¼Òµæ Áö¿ª¿¡¼´Â ³ôÀº Ä¡·áºñ°¡ ¿©ÀüÈ÷ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. À̵é Áö¿ª¿¡¼´Â ÀÇ·á ÀÎÇÁ¶ó°¡ ÃæºÐÇÏÁö ¾Ê¾Æ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ´õ¿í Á¦Çѵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯ÀüÀÚ Ä¡·á¿Í ¼öÇ÷ °ü·Ã ÇÕº´ÁõÀ» µÑ·¯½Ñ ±ÔÁ¦ ȯ°æÀº ½ÃÀå ÁøÀÔÀ» °¡·Î¸·´Â Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ƯÁ¤ ¹®È±Ç¿¡¼´Â À¯Àü¼º Áúȯ°ú °ü·ÃµÈ »çȸÀû ³«ÀÎÀÌ Ä¡·á ¹× °ËÁø ÇÁ·Î±×·¥ÀÇ º¸±ÞÀ» °¡·Î¸·´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ :
Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀº ƯÈ÷ À¯ÀüÀÚ Ä¡·á ¹× Áٱ⼼Æ÷ ¿¬±¸ ºÐ¾ß¿¡¼ ÁÖ¸ñÇÒ ¸¸ÇÑ ±âȸ¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, CRISPR ¹× ±âŸ À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó ƯÈ÷ °â»ó ÀûÇ÷±¸Áõ ¹× ¥â- ÁöÁßÇØºóÇ÷°ú °°Àº Áúº´¿¡ ´ëÇÑ ±Ùº»ÀûÀÎ Ä¡·á°¡ °¡´ÉÇØÁú ¼ö ÀÖ½À´Ï´Ù. ÀÎ½Ä Á¦°í, Áø´Ü ¼ºñ½º È®´ë, Ä¡·á Á¢±Ù¼ºÀÌ ³·Àº Áö¿ª¿¡¼ÀÇ Ä¡·á Á¢±Ù¼º °³¼±¿¡ ´ëÇÑ Á¤ºÎ ¹× ºñÁ¤ºÎ±â±¸(NGO)ÀÇ Âü¿© Áõ°¡´Â Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á ¹× ¿ø°ÝÀÇ·á ¼ºñ½ºÀÇ È®´ë´Â ƯÈ÷ Àü¹®ÀÇ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼ »õ·Î¿î ½ÃÀå ¼ºÀåÀÇ ±æÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Á¦¾àȸ»ç¿Í ÇаèÀÇ Àü·«Àû Á¦ÈÞ´Â Çì¸ð±Û·Îºó ÀÌ»ó Áúȯ¿¡ ´ëÇÑ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ°í ½ÅÁ¦Ç° °³¹ßÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
- Çì¸ð±Û·Îºó ÀÌ»óÁõ ¼¼°è ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
- ¾î¶² À¯ÇüÀÇ Ä¡·á ¹× ¿ä¹ýÀÌ Ã¤Å÷ü¿¡¼ ½ÃÀåÀ» ÁÖµµÇϰí Àִ°¡?
- À¯ÀüÀÚ Ä¡·áÀÇ ¹ßÀüÀº Ç÷»ö¼ÒÄ§ÂøÁõ ½ÃÀå °æÀï ±¸µµ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?
- Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾îµð¿¡ ÀÖÀ¸¸ç, °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
- Çì¸ð±Û·Îºó ÀÌ»óÁõ ¼¼°è ½ÃÀå¿¡¼ÀÇ »õ·Î¿î µ¿Çâ°ú Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå ºÐ·ù
Á¦3Àå ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀå ºÐ¼® ½Ã³ª¸®¿À
- °¡°Ý ºÐ¼®
- °¡°Ý°áÁ¤ ÀüÁ¦Á¶°Ç
- Áö¿ªº° °¡°Ý ºÐ¼®
- ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¹Ãø
- ½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
- Àý´ë¾× ±âȸ
- ½ÃÀå °³¿ä
- ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ º¸Çè »óȯ ½Ã³ª¸®¿À
Á¦4Àå ½ÃÀå ¿ªÇÐ
- °Å½Ã°æÁ¦ ¿äÀÎ
- ÃËÁø¿äÀÎ
- ¾ïÁ¦¿äÀÎ
- ±âȸ
- ÁÖ¿ä µ¿Çâ
- ¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦5Àå ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø : ÀûÀÀÁõº°
- ¼·Ð
- BPS(Basis Point Share) ºÐ¼® : ÀûÀÀÁõº°
- Àü³â´ëºñ ¼ºÀå ¿¹Ãø : ÀûÀÀÁõº°
- ½ÃÀå ±Ý¾× ¿¹Ãø, 2024-2033³â
- °â»ó ÀûÇ÷±¸Áõ
- º£Å¸ ÁöÁßÇØºóÇ÷
- ¾ËÆÄ ÁöÁßÇØºóÇ÷
- ½ÃÀåÀÇ ¸Å·Â : ÀûÀÀÁõº°
Á¦6Àå ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
- ¼·Ð
- BPS(Basis Point Share) ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
- Àü³â´ëºñ ¼ºÀå ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
- ½ÃÀå ±Ý¾× ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2024-2033³â
- ½ÃÀåÀÇ ¸Å·Â : ÃÖÁ¾»ç¿ëÀÚº°
Á¦7Àå ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°
- ¼·Ð
- BPS(Basis Point Share) ºÐ¼® : °Ë»ç À¯Çüº°
- Àü³â´ëºñ ¼ºÀå ¿¹Ãø : °Ë»ç À¯Çüº°
- ½ÃÀå ±Ý¾× ¿¹Ãø : °Ë»ç À¯Çüº°, 2024-2033³â
- Á¤±âÀûÀÎ ÀûÇ÷±¸¼ö(RBC) ÃøÁ¤
- À¯ÀüÀÚ °Ë»ç
- °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ¿¡ ÀÇÇÑ Çì¸ð±Û·Îºó
- Çì¸ð±Û·Îºó µîÀüÁ¡ Àü±â¿µµ¿(Hb IEF)
- Çì¸ð±Û·Îºó Àü±â¿µµ¿(Hb ELP)
- Çì¸ð±Û·Îºó ¿ëÇØµµ ½ÃÇè
- ½ÃÀåÀÇ ¸Å·Â : °Ë»ç À¯Çüº°
Á¦8Àå ¼¼°èÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°
- BPS(Basis Point Share) ºÐ¼® : ±¹°¡º°
- Àü³â´ëºñ ¼ºÀå ¿¹Ãø : ±¹°¡º°
- ½ÃÀå ±Ý¾× ¿¹Ãø : Áö¿ªº°
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀåÀÇ ¸Å·Â : ±¹°¡º°
Á¦9Àå ºÏ¹ÌÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø
Á¦11Àå À¯·´ÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø
Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀåÀÇ ºÐ¼®°ú ¿¹Ãø
- ¼·Ð
- BPS(Basis Point Share) ºÐ¼® : ±¹°¡º°
- Àü³â´ëºñ ¼ºÀå ¿¹Ãø : ±¹°¡º°
- ÁÖ¿ä Á¶»ç °á°ú
- ½ÃÀå ±Ý¾× ¿¹Ãø, ÀûÀÀÁõº°, 2024-2033³â
- °â»ó ÀûÇ÷±¸Áõ
- º£Å¸ ÁöÁßÇØºóÇ÷
- ¾ËÆÄ ÁöÁßÇØºóÇ÷
- ½ÃÀå ±Ý¾× ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº°, 2024-2033³â
- ½ÃÀå ±Ý¾× ¿¹Ãø, °Ë»ç À¯Çüº°, 2024-2033³â
- Á¤±âÀûÀÎ ÀûÇ÷±¸¼ö(RBC) ÃøÁ¤
- À¯ÀüÀÚ °Ë»ç
- °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ¿¡ ÀÇÇÑ Çì¸ð±Û·Îºó
- Çì¸ð±Û·Îºó µîÀüÁ¡ Àü±â¿µµ¿(Hb IEF)
- Çì¸ð±Û·Îºó Àü±â¿µµ¿(Hb ELP)
- Çì¸ð±Û·Îºó ¿ëÇØµµ ½ÃÇè
- ½ÃÀå ±Ý¾× ¿¹Ãø, ±¹°¡º°, 2024-2033³â
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âŸ ±¹°¡
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
- ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ : ¿µÇ⠺м®
Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Çì¸ð±Û·Îºó ÀÌ»óÁõ ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦14Àå °æÀï ±¸µµ
- °æÀï ´ë½Ãº¸µå
- ±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
- Abbott Diagnostics
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- Mindray Medical International Ltd
- Nexcelom Bioscience LLC.
- Nihon Kohden Europe Ltd
- PerkinElmer Inc.
- Siemens Healthineers
- Sysmex Europe GmbH
Á¦15Àå »ç¿ëµÇ´Â ÀüÁ¦ Á¶°Ç°ú µÎÀÚ¾î
Á¦16Àå Á¶»ç ¹æ¹ý
KSA
Persistence Market Research has recently published an extensive report on the global Hemoglobinopathy market. This report provides a detailed evaluation of the key market dynamics, including drivers, trends, opportunities, and challenges, delivering insightful perspectives into the market structure.
Key Insights:
- Hemoglobinopathy Market Size (2024E): USD 788.2 Bn
- Projected Market Value (2033F): USD 1472.3 Bn
- Global Market Growth Rate (CAGR 2024 to 2033): 7.2%
Hemoglobinopathy Market - Report Scope:
The Hemoglobinopathy market involves the diagnosis, treatment, and management of inherited disorders affecting the structure and function of hemoglobin in red blood cells. This market is primarily focused on conditions like sickle cell anemia, thalassemia, and other less common hemoglobin disorders. The market encompasses various products and services, including diagnostic tests, therapeutics, and gene therapies. Growth is fueled by increasing awareness, advancements in treatment options, and the rising incidence of these genetic disorders globally. Additionally, the market serves healthcare providers, hospitals, clinics, and research institutions, addressing the growing demand for early diagnosis and treatment interventions.
Market Growth Drivers:
Several key factors are driving the global Hemoglobinopathy market. First and foremost, the rising prevalence of hemoglobin disorders, especially in regions like sub-Saharan Africa, South Asia, and the Mediterranean, has spurred demand for better diagnosis and treatment solutions. Increased awareness about these conditions, along with government initiatives to provide early screening programs, has also fueled market expansion. Advances in gene therapy and novel treatment options, such as CRISPR technology for genetic correction, offer promising avenues for curing these disorders. Furthermore, a growing focus on prenatal diagnosis and carrier screening is helping prevent the transmission of hemoglobinopathies, contributing to market growth.
Market Restraints:
Despite its promising outlook, the Hemoglobinopathy market faces certain challenges. High treatment costs, especially for advanced gene therapies, remain a significant barrier in many low-income regions where the prevalence of hemoglobin disorders is the highest. The lack of sufficient healthcare infrastructure in these areas further limits access to effective treatments. Additionally, the regulatory environment surrounding gene therapies and blood transfusion-related complications poses hurdles for market participants. Finally, the social stigma associated with genetic disorders in certain cultures hinders the uptake of treatment and screening programs.
Market Opportunities:
The Hemoglobinopathy market presents notable opportunities, particularly in the areas of gene therapy and stem cell research. As ongoing research in CRISPR and other gene-editing technologies progresses, there is potential for curative treatments, especially for conditions like sickle cell disease and beta-thalassemia. Increasing government and non-government organization (NGO) involvement in raising awareness, expanding diagnostic services, and improving access to treatment in underserved regions presents a significant growth opportunity. Additionally, the expansion of telemedicine and remote healthcare services offers new avenues for market growth, especially in regions with limited access to specialist care. Furthermore, strategic collaborations between pharmaceutical companies and academic institutions can drive innovation and foster new product developments in the Hemoglobinopathy landscape.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the global Hemoglobinopathy market?
- Which types of treatments and therapies are leading the market in terms of adoption?
- How are advancements in gene therapy influencing the competitive landscape of the Hemoglobinopathy market?
- Who are the key players in the Hemoglobinopathy market, and what strategies are they employing to stay competitive?
- What are the emerging trends and future prospects in the global Hemoglobinopathy market?
Competitive Intelligence and Business Strategy:
Key players in the global Hemoglobinopathy market, such as Novartis AG, Global Blood Therapeutics, and Bluebird Bio, Inc., focus on innovation and strategic partnerships to gain a competitive edge. These companies invest heavily in research and development (R&D) to develop advanced gene therapies, such as LentiGlobin for treating thalassemia and sickle cell disease. Collaborations with research institutions and healthcare providers are crucial for expanding access to these therapies in regions where the prevalence of hemoglobin disorders is high. Moreover, emphasis on affordable treatment solutions, patient education, and advocacy for early screening programs fosters market growth and enhances brand loyalty in the evolving Hemoglobinopathy landscape.
Key Companies Profiled:
- Abbott Diagnostics
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- Mindray Medical International Ltd
- Nexcelom Bioscience LLC.
- Nihon Kohden Europe Ltd
- PerkinElmer Inc.
- Siemens Healthineers
- Sysmex Europe GmbH
- Others
Hemoglobinopathy Industry Segmentation:
By Disorder Type:
- Sickle Cell Disease
- Alpha Thalassemia
- Beta Thalassemia
- Hemoglobin C Disease
- Hemoglobin S-C Disease
- Others
By Diagnostic Type:
- Genetic Testing
- Blood Tests
- Hemoglobin Electrophoresis
- High-Performance Liquid Chromatography (HPLC)
- Others
By Treatment Type:
- Blood Transfusion Therapy
- Pharmacotherapy
- Gene Therapy
- Stem Cell Transplant
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- East Asia
- Middle East & Africa
Table of Contents
1. Executive Summary
2. Market Taxonomy
3. Global Hemoglobinopathy Market Analysis Scenario
- 3.1. Pricing Analysis
- 3.1.1. Pricing Assumptions
- 3.1.2. Price Analysis per Region
- 3.2. Market Size (US$ Bn) and Forecast
- 3.2.1. Market Size and Y-o-Y Growth
- 3.2.2. Absolute $ Opportunity
- 3.3. Market Overview
- 3.3.1. Global Hemoglobinopathy Market Reimbursement Scenario
4. Market Dynamics
- 4.1. Macro-economic Factors
- 4.2. Drivers
- 4.2.1. Supply Side
- 4.2.2. Demand Side
- 4.3. Restraints
- 4.4. Opportunity
- 4.5. Key Trends
- 4.6. Forecast Factors - Relevance and Impact
5. Global Hemoglobinopathy Market Analysis and Forecasts, by Indication
- 5.1. Introduction
- 5.2. Basis Point Share (BPS) Analysis by Indication
- 5.3. Y-o-Y Growth Projections by Indication
- 5.4. Market Value Forecast, 2024-2033
- 5.4.1. Sickle Cell Disease
- 5.4.2. Beta Thalassemia
- 5.4.3. Alpha Thalassemia
- 5.5. Market Attractiveness by Indication
6. Global Hemoglobinopathy Market Analysis and Forecasts, by End User
- 6.1. Introduction
- 6.2. Basis Point Share (BPS) Analysis by End User
- 6.3. Y-o-Y Growth Projections by End User
- 6.4. Market Value Forecast by End User, 2024-2033
- 6.4.1. Hospitals
- 6.4.2. Diagnostics Laboratories
- 6.4.3. Clinics
- 6.5. Market Attractiveness by End User
7. Global Hemoglobinopathy Market Analysis and Forecasts, by Test Type
- 7.1. Introduction
- 7.2. Basis Point Share (BPS) Analysis by Test Type
- 7.3. Y-o-Y Growth Projections by Test Type
- 7.4. Market Value Forecast by Test Type, 2024-2033
- 7.4.1. Routine Red Blood Cell (RBC) Count
- 7.4.2. Genetic Testing
- 7.4.3. Hemoglobin by High Performance Liquid Chromatography
- 7.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
- 7.4.5. Hemoglobin electrophoresis (Hb ELP)
- 7.4.6. Hemoglobin Solubility Test
- 7.5. Market Attractiveness by Test Type
8. Global Hemoglobinopathy Market Analysis and Forecasts, by Region
- 8.1. Basis Point Share (BPS) Analysis by Country
- 8.2. Y-o-Y Growth Projections by Country
- 8.3. Market Value Forecast by Region
- 8.3.1. North America
- 8.3.2. Latin America
- 8.3.3. Europe
- 8.3.4. APAC
- 8.3.5. MEA
- 8.4. Market Attractiveness by Country
9. North America Hemoglobinopathy Market Analysis and Forecast
- 9.1. Introduction
- 9.1.1. Basis Point Share (BPS) Analysis by Country
- 9.1.2. Y-o-Y Growth Projections by Country
- 9.1.3. Key Findings
- 9.2. Market Value Forecast by Indication, 2024-2033
- 9.2.1. Sickle Cell Disease
- 9.2.2. Beta Thalassemia
- 9.2.3. Alpha Thalassemia
- 9.3. Market Value Forecast by End User, 2024-2033
- 9.3.1. Hospitals
- 9.3.2. Diagnostics Labs
- 9.3.3. Clinics
- 9.4. Market Value Forecast by Test Type, 2024-2033
- 9.4.1. Routine Red Blood Cell (RBC) Count
- 9.4.2. Genetic Testing
- 9.4.3. Hemoglobin by High Performance Liquid Chromatography
- 9.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
- 9.4.5. Hemoglobin electrophoresis (Hb ELP)
- 9.4.6. Hemoglobin Solubility Test
- 9.5. Market Value Forecast by Country, 2024-2033
- 9.6. Market Attractiveness Analysis
- 9.6.1. by Indication
- 9.6.2. by End User
- 9.6.3. by Test Type
- 9.7. Drivers and Restraints: Impact Analysis
10. Latin America Hemoglobinopathy Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Basis Point Share (BPS) Analysis by Country
- 10.1.2. Y-o-Y Growth Projections by Country
- 10.1.3. Key Findings
- 10.2. Market Value Forecast by Indication, 2024-2033
- 10.2.1. Sickle Cell Disease
- 10.2.2. Beta Thalassemia
- 10.2.3. Alpha Thalassemia
- 10.3. Market Value Forecast by End User, 2024-2033
- 10.3.1. Hospitals
- 10.3.2. Diagnostics Labs
- 10.3.3. Clinics
- 10.4. Market Value Forecast by Test Type, 2024-2033
- 10.4.1. Routine Red Blood Cell (RBC) Count
- 10.4.2. Genetic Testing
- 10.4.3. Hemoglobin by High Performance Liquid Chromatography
- 10.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
- 10.4.5. Hemoglobin electrophoresis (Hb ELP)
- 10.4.6. Hemoglobin Solubility Test
- 10.5. Market Value Forecast by Country, 2024-2033
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Mexico
- 10.5.4. Rest of Latin America
- 10.6. Market Attractiveness Analysis
- 10.6.1. by Indication
- 10.6.2. by End User
- 10.6.3. by Test Type
- 10.7. Drivers and Restraints: Impact Analysis
11. Europe Hemoglobinopathy Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Basis Point Share (BPS) Analysis by Country
- 11.1.2. Y-o-Y Growth Projections by Country
- 11.1.3. Key Findings
- 11.2. Market Value Forecast by Indication, 2024-2033
- 11.2.1. Sickle Cell Disease
- 11.2.2. Beta Thalassemia
- 11.2.3. Alpha Thalassemia
- 11.3. Market Value Forecast by End User, 2024-2033
- 11.3.1. Hospitals
- 11.3.2. Diagnostics Labs
- 11.3.3. Clinics
- 11.4. Market Value Forecast by Test Type, 2024-2033
- 11.4.1. Routine Red Blood Cell (RBC) Count
- 11.4.2. Genetic Testing
- 11.4.3. Hemoglobin by High Performance Liquid Chromatography
- 11.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
- 11.4.5. Hemoglobin electrophoresis (Hb ELP)
- 11.4.6. Hemoglobin Solubility Test
- 11.5. Market Value Forecast by Country, 2024-2033
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Poland
- 11.5.7. Russia
- 11.5.8. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. by Indication
- 11.6.2. by End User
- 11.6.3. by Test Type
- 11.7. Drivers and Restraints: Impact Analysis
12. APAC Hemoglobinopathy Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Basis Point Share (BPS) Analysis by Country
- 12.1.2. Y-o-Y Growth Projections by Country
- 12.1.3. Key Findings
- 12.2. Market Value Forecast by Indication, 2024-2033
- 12.2.1. Sickle Cell Disease
- 12.2.2. Beta Thalassemia
- 12.2.3. Alpha Thalassemia
- 12.3. Market Value Forecast by End User, 2024-2033
- 12.3.1. Hospitals
- 12.3.2. Diagnostics Labs
- 12.3.3. Clinics
- 12.4. Market Value Forecast by Test Type, 2024-2033
- 12.4.1. Routine Red Blood Cell (RBC) Count
- 12.4.2. Genetic Testing
- 12.4.3. Hemoglobin by High Performance Liquid Chromatography
- 12.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
- 12.4.5. Hemoglobin electrophoresis (Hb ELP)
- 12.4.6. Hemoglobin Solubility Test
- 12.5. Market Value Forecast by Country, 2024-2033
- 12.5.1. China
- 12.5.2. India
- 12.5.3. Japan
- 12.5.4. Australia
- 12.5.5. Rest of APAC
- 12.6. Market Attractiveness Analysis
- 12.6.1. by Indication
- 12.6.2. by End User
- 12.6.3. by Test Type
- 12.7. Drivers and Restraints: Impact Analysis
13. MEA Hemoglobinopathy Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Basis Point Share (BPS) Analysis by Country
- 13.1.2. Y-o-Y Growth Projections by Country
- 13.1.3. Key Findings
- 13.2. Market Value Forecast by Indication, 2024-2033
- 13.2.1. Sickle Cell Disease
- 13.2.2. Beta Thalassemia
- 13.2.3. Alpha Thalassemia
- 13.3. Market Value Forecast by End User, 2024-2033
- 13.3.1. Hospitals
- 13.3.2. Diagnostics Labs
- 13.3.3. Clinics
- 13.4. Market Value Forecast by Test Type, 2024-2033
- 13.4.1. Routine Red Blood Cell (RBC) Count
- 13.4.2. Genetic Testing
- 13.4.3. Hemoglobin by High Performance Liquid Chromatography
- 13.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
- 13.4.5. Hemoglobin electrophoresis (Hb ELP)
- 13.4.6. Hemoglobin Solubility Test
- 13.5. Market Value Forecast by Country, 2024-2033
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of MEA
- 13.6. Market Attractiveness Analysis
- 13.6.1. by Indication
- 13.6.2. by End User
- 13.6.3. by Test Type
- 13.7. Drivers and Restraints: Impact Analysis
14. Competition Landscape
- 14.1. Competition Dashboard
- 14.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 14.2.1. Abbott Diagnostics
- 14.2.2. Bio-Rad Laboratories, Inc.
- 14.2.3. Danaher Corp.
- 14.2.4. Mindray Medical International Ltd
- 14.2.5. Nexcelom Bioscience LLC.
- 14.2.6. Nihon Kohden Europe Ltd
- 14.2.7. PerkinElmer Inc.
- 14.2.8. Siemens Healthineers
- 14.2.9. Sysmex Europe GmbH
15. Assumptions and Acronyms Used
16. Research Methodology